5-Amino-1MQ vs SS-31
Both 5-Amino-1MQ and SS-31 are used for longevity. Here's how their evidence, dosing, and regulatory status actually compare.
5-Amino-1MQ
Evidence C+5-Amino-1-Methylquinolinium
A small-molecule NNMT inhibitor that has produced fat loss and improved muscle stem-cell function in obese rodents. No human RCTs yet.
View full 5-Amino-1MQ profile →SS-31
Evidence B+Elamipretide (SS-31)
A cell-permeable tetrapeptide that targets cardiolipin in the inner mitochondrial membrane. Investigated for primary mitochondrial myopathy, heart failure, and dry age-related macular degeneration.
View full SS-31 profile →Side-by-Side
| Attribute | 5-Amino-1MQ | SS-31 |
|---|---|---|
| Evidence Grade | C+ | B+ |
| FDA Status | Not FDA-approved — small-molecule research compound (NNMT inhibitor) | Not FDA-approved — Phase 3 trials for primary mitochondrial myopathy |
| Typical Dose | 50–150 mg orally daily (research-only) | Trial range: 40 mg subcutaneous daily |
| Clinics Indexed | 31 | 29 |
| Categories | fat-loss, longevity | mitochondrial, longevity |
Key reported benefits — 5-Amino-1MQ
- ✓NNMT inhibition
- ✓Fat-mass reduction (preclinical)
- ✓Muscle stem-cell support
Key reported benefits — SS-31
- ✓Mitochondrial cardiolipin support
- ✓ATP production
- ✓Reduced oxidative damage
Educational use only
This comparison is for educational purposes and not medical advice. Peptide selection should be made with a licensed medical professional based on your individual goals, health history, and current evidence quality.